

PurifLOH Limited

ABN: 11 124 426 339

Reporting Period: For the year ended 30 June 2023

Previous Period: For the year ended 30 June 2022

Principal Activities and Review of Operations

Results for Announcement to Market	\$ Change	% Change	12 months to 30 June 2023 \$	12 months to 30 June 2022 \$
Revenue from ordinary activities	(74,489)	(93.4%)	5,240	79,729
Profit/(loss) after tax from ordinary activities attributable to members	(430,531)	182%	(667,401)	(237,050)
Profit/(loss) attributable to members	(430,351)	182%	(667,401)	(237,050)

Earnings Per Share	30 June 2023 Cents	30 June 2022 Cents
Basic loss per share - weighted average	(2.088)	(0.752)
Diluted loss per share - weighted average	(2.088)	(0.752)

Dividend Information	Amount per share	Franked Amount per share
Dividend – current reporting period	Nil	Nil
Dividend – previous reporting period	Nil	Nil

Net Tangible Asset Backing per Ordinary Share	Cents
Net tangible asset backing per ordinary share – current reporting period	(9.04)
Net tangible asset backing per ordinary share – previous reporting period	(6.56)

Commentary on the Results for the Period

The loss results from normal operating expenses of the company associated with its ongoing research and development program for the Free Radical Generator.

Attachments

The following documents are attached:

- Explanation of Principal Activities and Review of Operations
- The Preliminary Final Report of PurifLOH Limited for the year ended 30 June 2023

Audit Status

This Preliminary Final Report is based on the Annual Financial Report which is in the process of being audited.

Control gained over entities

None

Loss of control over entities

None

Current period

There were no dividends paid, recommended or declared during the current year.

Previous period

There were no dividends paid, recommended or declared during the previous period

Dividend reinvestment plans

None

Details of associates and joint venture entities

None

Foreign entities

None

Any other significant information

None

Carl Le Souef
Chairman

Dated at Melbourne this 31st day of August 2023

PuriflOH Limited (“PuriflOH”, “PO3” or “Company”), continues with the development of its Free Radical Generator (“FRG”) technology for a range of applications. The applications are broadly across three opportunities:

- Indoor air purification;
- Water sanitation; and
- Medical sterilisation.

The Company has been expanding the potential of the technology within these opportunities as well as considering additional opportunities within other sectors such as agriculture.

In continuing to move forward with the technology the Company has moved its R&D work to Australia under the oversight of Dr. Alex Sava and Mr. Vigneswaran Appia. To that end the ACERT Product has been developed to clean air-conditioning coils, a common source of air contamination within the home and office.

Further agreement has been reached with Osmoflo Limited to further explore the commercial opportunities of the FRG technology in the water sector, with specific interest in the destruction of PFAS and other speciality applications where existing solutions are not ideal.

About the FRG Technology

The FRG technology produces a range of Reactive Oxygen Species (“ROS”) that include the hydroxyl radical ($OH\cdot$), superoxide radical (O_2^-), oxygen radical ($O\cdot$) and the ozone molecule – all of which are amongst the most highly oxidative species known as indicated by the table below.

Oxidizing Agent	Oxidation Potential (V)
Fluorine	3.06
Hydroxyl radical	2.80
Oxygen (atomic)	2.42
Ozone	2.08
Hypochlorite	1.49
Chlorine	1.36
Hydrogen peroxide	1.78
Chlorine dioxide	1.27
➤ Oxygen (molecular)	1.23

The effectiveness of oxidising radicals in purification, sanitation and sterilisation has long been known. The challenge for widespread adoption has been reliable and cost-effective production of the radicals themselves. The radicals have a short half-life and as a result they cannot be stored nor transported. To deploy and maximise the power of these radicals requires a robust, reliable and cost effective in-situ production system.

The Company’s development program aims to provide systems with these characteristics. Using one flexible core technology, the objective of these applications is the purification of air, the purification of water and then ability to sterilize medical equipment and facilities.

During the year the Company focused on the development opportunities within the air, surface disinfection and water treatment sectors.

For personal use only

PURIFLOH LIMITED

Preliminary Final Report

30 June 2023

General Information

The financial statements cover PuriflOH Limited. They are presented in Australian dollars, which is PuriflOH Limited’s functional and presentation currency.

The preliminary financial statements were authorised for issue, in accordance with a resolution of directors, on 31 August 2023. The directors have the power to amend and reissue the financial statements.

For personal use only

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the twelve months ended 30 June 2023

	Note	30 June 2023 \$	30 June 2022 \$
Revenue			
Revenue from continuing operations		5,240	79,729
Other Income			
Realised FX Gain		-	147
Unrealised FX Gain		334,563	696,494
Total Other Income		339,803	776,370
Research and Development – Somnio		-	(79,729)
Accounting and audit	2	(157,815)	(158,940)
Other Expenses	2	(579,431)	(728,245)
Share Based Payments		(195,000)	-
Finance costs		(74,958)	(46,506)
Total expense		(1,007,204)	(1,013,420)
Profit/(Loss) before income tax		(667,401)	(237,050)
Income tax expense		-	-
Net profit/(loss) for the period		(667,401)	(237,050)
Other Comprehensive Income			
Items that may be reclassified to profit or loss			
Exchange differences on translating foreign operations		(366,248)	(764,108)
Total Comprehensive Income/(Loss) for the period		(1,033,649)	(1,001,158)
Attributable to owners of the parent entity		(1,033,649)	(1,001,158)
Basic earnings Profit/(loss) per share (cents)		(2.088)	(0.752)
Diluted earnings Profit/(loss) per share (cents)		((2.088)	(0.752)

The Consolidated Statement of Profit or Loss and Other Comprehensive Income above should be read in conjunction with the accompanying notes.

For personal use only

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2023

	Note	30 June 2023 \$	30 June 2022 \$
Assets			
Current Assets			
Cash and cash equivalents		9,239	16,912
Trade and other receivables		14,678	7,356
Prepayments		12,302	12,447
Total Current Assets		36,219	36,716
Non-Current Assets			
Intangible assets - trade marks		60,026	63,663
Total Non-Current Assets		60,026	63,663
Total Assets		96,245	100,379
Liabilities			
Current Liabilities			
Trade and other payables		2,087,442	1,527,152
Total Current Liabilities	3	2,087,442	1,527,152
Non-Current Liabilities			
Borrowings – Dilato		916,540	642,315
Total Non-Current Liabilities		916,540	642,315
Total Liabilities		3,003,982	2,169,467
Net Assets/(Liabilities)		(2,907,737)	(2,069,088)
Equity/ (Shareholders' Deficit)			
Contributed equity		84,547,846	84,352,846
Foreign exchange translation reserve		(496,048)	(129,800)
Accumulated losses		(86,959,535)	(86,292,134)
Total Equity/ (Shareholders' Deficit)		(2,907,737)	(2,069,088)

The Consolidated Statement of Financial Position above should be read in conjunction with the accompanying notes.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the 12 months ended 30 June 2023

	Contributed Equity	Foreign Currency Translation Reserve	Accumulated losses	Total
	\$	\$	\$	\$
Balance at 30 June 2022	84,352,846	(129,800)	(86,292,134)	(2,069,088)
Shares issued	195,000			195,000
Profit/(Loss) for the period	-	-	(667,401)	(667,401)
Other comprehensive income	-	(366,248)	-	(366,248)
Total comprehensive income (loss) for the period	-	(366,248)	(667,401)	(1,033,649)
Balance at 30 June 2023	84,547,846	(496,048)	(86,959,535)	(2,907,737)

For the 12 months ended 30 June 2022

	Contributed Equity	Foreign Currency Translation Reserve	Accumulated losses	Total
	\$	\$	\$	\$
Balance at 30 June 2021	84,352,846	634,308	(86,055,084)	(1,067,930)
Profit/(Loss) for the period	-	-	(237,050)	(237,050)
Other comprehensive income	-	(764,108)	-	(764,108)
Total comprehensive income (loss) for the period	-	(764,108)	(237,050)	(1,001,158)
Balance at 30 June 2022	84,352,846	(129,800)	(86,292,134)	(2,069,088)

The Consolidated Statement of Changes in Equity above should be read in conjunction with the accompanying notes.

For personal use only

CONSOLIDATED STATEMENT OF CASH FLOWS

For the 12 months ended 30 June 2023

Note	30 June 2023 \$	30 June 2022 \$
Cash flows related to operating activities		
Receipts from customers	5,764	79,729
Interest Received	-	-
Payments for research and development and other expenditure	(286,413)	(584,055)
Net operating cash flows	(280,649)	(504,326)
Cash flows related to investing activities		
Purchase of intangibles	-	-
Net investing cash flows	-	-
Cash flows related to financing activities		
Proceeds from Dilato Facility	274,225	490,726
Net financing cash flows	274,225	490,726
Net increase / (decrease) in cash held	(6,424)	(13,600)
Net foreign exchange differences	(1,249)	294
Cash and cash equivalents at beginning of the period	16,912	30,218
Cash and Cash Equivalents at the end of the period	9,239	16,912

The Consolidated Statement of Cash Flows above should be read in conjunction with the accompanying notes.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1. General Information

PuriflOH Limited (“PuriflOH”, “the Company” or “PO3”) is a public company, incorporated and domiciled in Australia. The Company listed on the Australian Securities Exchange (ASX) on 30 December 2010.

Basis of Preparation – Accounting policies, estimation methods and measurement bases

These preliminary statements have been prepared in accordance with the ASX listing rules and do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the financial statements for the year ended 30 June 2022 and any public announcements made by the company during the reporting period in accordance with continuous disclosure requirements of the *Corporations Act 2001*.

Accounting policies, estimation methods and measurement bases used in this Appendix 4E are the same as those used in the last annual report and the last half-year report except as described below.

Going Concern

The directors of PuriflOH Limited have prepared the Preliminary Financial Report of PuriflOH Limited on a going concern basis which contemplates the continuity of normal business activity and the realisation of assets and settlement of liabilities in the normal course of business.

The continuation of the Group as a going concern is dependent upon its ability to achieve or maintain the following:

- The continued financial support from the Dilato facility (being a \$3m facility with a maturity date of 31 December 2024);
- The continued support of creditors;
- The ability to raise additional capital or attract alternate sources of funding; and
- The generation of cash inflows resulting from successful engagement with OEM’s.

Accordingly, the Directors believe that based on the above, and other strategies implemented, the Group has access to sufficient funding for at least the next 12 months from the date of this report.

2. Other Expenses and Accounting Expenses

Loss before income tax includes the following specific items:

Other Expenses	30 June 2023 \$	30 June 2022 \$
ASX Fees	30,099	41,435
Share Registry Services	14,963	23,133
Serviced Office	90,000	90,000
Legal Fees	7,155	5,043
Insurance	66,805	77,305
Directors Fees	302,004	302,004
Consulting - Other	-	97,956
Other	68,405	91,369
	579,431	728,245

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Accounting and Audit Expenses	30 June 2023 \$	30 June 2022 \$
Accounting Fees	123,400	126,889
Audit Fees	34,415	32,051
	157,815	158,940

3. Current Liabilities

Current	30 June 2023 \$	30 June 2022 \$
---------	--------------------	--------------------

Trade payables	14,991	19,356
Accruals	23,000	22,700
USA Trade and Other payables	846,360	805,011
Other related parties		
Directors' Fees	587,090	295,086
Others	616,000	385,000
Balance	2,087,441	1,527,152

4. Contributed Equity

12 months ended 30 June 2023	No. of shares	\$
At 1 July 2022	31,523,498	84,352,846
Share issue (i)	650,000	195,000
As at 30 June 2023	32,173,498	84,547,846

(i) the Company issued 650,000 free shares to consultants assisting the Company for service recognition.

5. Significant Events after Balance Sheet Date

On 10 July 2023, Mr. John Evans resigned from the Company. It was agreed to issue Mr. Evans 150,000 shares in the Company in lieu of outstanding fees (subject to the shareholder approval at the next AGM).

6. Interests in Subsidiaries

The consolidated financial statements include the financial statements of PurifIOH and its subsidiaries listed in the following table:

Name	Country of Incorporation	Equity Interest	
		2023	2022
PurifIOH USA Incorporated	United States	100%	100%

The Company has a US subsidiary called Purifloh USA Incorporated. This subsidiary was incorporated in Delaware, USA in late 2018. The subsidiary carries a subscription of shares of common stock with par value of US\$0.001 of which PurifIOH Limited owns 100%. As a result of this establishment, the financial statements reflect the consolidation position of the parent and the subsidiary collectively as the Group.

The purpose of this entity is to manage operations in the US as the Company moves forward with its commercialization plans for the Free Radical Generator.